tradingkey.logo

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

ReutersMay 27, 2025 1:06 PM

- Tvardi Therapeutics Inc TVRD.O:

  • TVARDI THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TTI-101 IN IDIOPATHIC PULMONARY FIBROSIS

  • TVARDI THERAPEUTICS INC - TOPLINE DATA FROM REVERT IPF TRIAL EXPECTED IN Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI